Q2 2025

Filed Aug 14, 2025 · 10-Q · 45 days after period end · 0001410578-25-001826

Q2 2025 · 10-Q

Revenue

$861.18K

−26.3% vs Q2 2024

Net Income

-$4.02M

N/M vs Q2 2024

EPS Diluted

-$0.29

N/M vs Q2 2024

Operating Income-$5,122,217N/M

Operating Cash Flow

Same quarter

Metric	Q2 2025	Q2 2024	Q2 2023	Q2 2022
Revenue	$861.18K	$1.17M	$762.66K	$790.51K
Net Income	-$4.02M	-$2.19M	$2.52M	-$9.24M
EPS Diluted	-$0.29	-$0.25	$0.29	-$1.11

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Marker Therapeutics, Inc. · CIK 1094038 · Engraved from SEC EDGAR